Get 40% Off
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks!Unlock list

Asterias Biotherapeutics reports milestone targets for 2018

Published 01/04/2018, 09:04 AM
© Reuters.  Asterias Biotherapeutics reports milestone targets for 2018
  • Asterias Biotherapeutics (NYSEMKT:AST) provides the following 2018 milestones targets for its spinal cord injury and cancer immunotherapy programs.
  • AST-OPC1 – Spinal Cord Injury: The Company expects to report 6-month and 12 month data from Cohort 3 (AIS-A 20M-cell cohort) and Cohort 4 (AIS-B 10M-cell cohort) in February and in August respectively and results for the entire study in December.
  • AST-VAC2 – Allogeneic Cancer Immunotherapy: The Company anticipates to report the initial safety and immunogenicity readouts of the study enrolling 24 patients in H2 2018.
  • Cash and cash equivalents as on December 31, 2017 were ~$21.6M. During Q4, the Company completed a registered direct offering that raised ~$10.4M in gross proceeds.
  • Now read: Redhill Pharma: Gut-Punch Lessons


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.